Speedel Stops Current SPP301 Phase III Trial in Diabetic Kidney Disease in the Interests of Patient Safety
December 19, 2006 01:26 ET
|
Speedel
BASEL, Switzerland and BRIDGEWATER, N.J., Dec. 19, 2006 (PRIME NEWSWIRE) -- Speedel (SWX:SPPN) announced today that in the interests of patient safety it has stopped the current pivotal Phase III...
Speedel: Up to 3 Month Extension of U.S. Regulatory Review Period for SPP100
December 14, 2006 01:41 ET
|
Speedel
BASEL, Switzerland and BRIDGEWATER, N.J., Dec. 14, 2006 (PRIME NEWSWIRE) -- Speedel (SWX:SPPN) notes today's announcement by Novartis that the U.S. regulatory review period has been extended by up to...
Speedel Holds Annual R&D Day
November 29, 2006 01:31 ET
|
Speedel
BASEL, Switzerland and BRIDGEWATER, N.J., Nov. 29, 2006 (PRIME NEWSWIRE) -- Speedel (SWX:SPPN) today holds its annual Research & Development Day. The event is being held in Basel, and attended by...
Speedel Presents SPP200 Positive Safety and Efficacy Results
November 17, 2006 16:59 ET
|
Speedel
BASEL, Switzerland and BRIDGEWATER, N.J., Nov. 17, 2006 (PRIMEZONE) -- Speedel (SWX:SPPN) today announced that it is very pleased with the Phase II clinical data on SPP200 in the treatment of 127...
Speedel Announces Financial Results for Third Quarter 2006
November 15, 2006 01:36 ET
|
Speedel
BASEL, Switzerland and BRIDGEWATER N.J., Nov. 15, 2006 (PRIMEZONE) -- Speedel (SWX:SPPN) today announced financial results for the nine months ending September 30, 2006.
Financial Highlights
--...
Speedel Begins Phase IIa Trial With Next Generation Renin Inhibitor
October 31, 2006 01:54 ET
|
Speedel
BASEL, Switzerland and BRIDGEWATER, N.J., Oct. 31, 2006 (PRIMEZONE) -- Speedel (SWX:SPPN) announces that it has reached another significant milestone in the development of its family of renin...